For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need.
Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

94% of all revenue goes towards our programs, with only 6% towards MANAGEMENT AND GENERAL EXPENSES.

PANCREATIC CANCER DIAGNOSIS

Signs and Symptoms

Generally, the diagnosis of early pancreatic cancer (adenocarcinoma of the pancreas) is very difficult. The most common symptoms of cancer of the pancreas include loss-of-appetite, weight loss, abdominal discomfort and nausea. As these are all fairly non-specific symptoms, there is often delay in getting to the final diagnosis. The most common physical sign of pancreatic cancer is jaundice, with or without associated itching. Proceeding to a medical evaluation often requires a high index of suspicion by the patient or by medical personnel who are experienced with the presentation of early pancreatic cancer.

Laboratory

Often lab results in pancreatic cancer show a high bilirubin (yellowish bile pigment found in the serum) and elevated liver function enzymes. The CA 19-9 marker, a Lewis blood group-related mucin, is frequently elevated in pancreatic cancer, but its use as a sole agent in the screening for or diagnosis of cancer of the pancreas is not presently a fully accepted practice. High CA 19-9 levels may tend to be associated with (but do not always indicate) larger sized tumors and with a decreased likelihood of surgical resectability. The use of this marker is more universally accepted as a running measure within a particular individual (after diagnosis), to help reflect the stability, response, or progression of pancreatic cancer to treatment.

 

Staging Studies

The main reason for the diagnostic staging of pancreatic cancer is to try to chart the best course for treatment, especially to help decide whether a patient is a candidate for surgical resection. There is a great deal of flux and controversy in these areas of diagnoses; there are institutional and even geographical variations in considered opinions as to the correct approaches in regard to these diagnosis / staging techniques. Also, there may be great variability in the experience level of the operators and evaluators of a given diagnostic procedure – thus (perhaps rightfully) coloring the institution’s approach at recommending which diagnostic studies are used. In the context of these understandings, the following brief overview will try and point out some strengths and weaknesses of certain of the current diagnosis staging procedures.

Generally, in the U.S., the dynamic spiral (or helical) CT scan with IV and oral contrast media enhancement is considered to be the procedure of choice for the diagnosis / staging of pancreatic cancer. With the latest equipment and with experienced operators and evaluators, this approach at diagnosis can detect up to 90-95% of cancer of the pancreas. Specific pancreatic cancer tumors that are greater than ½ to one inch in diameter can usually be detected. These CTs can predict unresectability about 90% of the time; but are less accurate at predicting surgical resectability. Its diagnostic strength in this regard is related to its ability to demonstrate pancreatic extension involving local arteries. This technique is less reliably able to show subtle local vein involvement, to detect or diagnose small liver metastasis or to pick up lymph node involvement in pancreatic cancer.

Transabdominal ultrasound is a more popular diagnostic procedure for pancreatic cancer outside of the U.S. where operators are more experienced and generally the patient-population may be less obese – a big problem in imaging structures through the abdomen. In experienced hands, with a thin patient and with good equipment, this ultrasound approach can often diagnose or detect smaller pancreatic cancer tumors than are even found by the CT procedure.

Two other ultrasound procedures are of note. The endoscopic ultrasound (ultrasound through a tube which is placed down the esophagus) can be very good at finding small tumors in the pancreas. And laparoscopic ultrasound (ultrasound through a small tube placed through the abdomen into the region of the pancreas) is sensitive at finding liver and peritoneal involvement in pancreatic cancer, without having to resort to full surgery.

Pre-operative angiography (viewing contrast dye placed in select arteries) is recommended by some surgeons for pancreatic cancer diagnosis and staging, although the introduction of spiral CT has provided a competing option.

CT or ultrasound-guided percutaneous biopsy (via needle) can retrieve a bit of pancreatic tumor tissue for histologic (microscopic) viewing without requiring full pancreatic cancer surgery. There exists some concern about the risk of inadvertent “seeding” of the tumor into the peritoneum with this technique, but some experts feel that the potential risks outweigh the potential harm in selected cases.

Often an institution will have a coordinated approach at the diagnosis and staging of pancreatic cancer. For example, a spiral CT procedure might be done first. If it appears that there is a pancreatic cancer tumor and that it might be resectable, the next step might be a diagnostic laparoscopy (for direct visualization) – with perhaps a peritoneal wash (to check for malignant pancreatic cancer cells in the peritoneum) and with or without a laparoscopic ultrasound exam. If evidence of unresectability is found, a percutaneous biopsy might be done, to fully establish the diagnosis of the type of pancreatic cancer and to help with medical treatment planning. If no evidence of unresectability is found, then a full abdominal surgery might typically ensue to further evaluate the clinical status with an aim of the diagnosis of pancreatic cancer – and if finally so indicated to proceed with the most appropriate surgical procedure.

ABSTRACTS:

The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic.These abstracts can be searched Here.

  • 1-Jul-16 – Exosome scrutiny for early diagnosis of adenomacarcinoma of the pancreas  
  • 1-Jul-16 – Kras mutations in pancreatic “juice” for diagnosis of adenocarcinoma of the pancreas 
  • 1-Feb-14 – MRI in the Identification of Cystic Pancreatic Tumors
  • 21-Mar-13 – Fine Needle Biopsy via Esophageal Ultrasound in Small Pancreatic Tumors
  • 1-Jan-13 – Timed Breathing Radiographic Procedures for Pancreatic Cancer Diagnosis
  • 1-Dec-12 – CTC Diagnosis in Cancer of the Pancreas
  • 1-Nov-12 – Multiple Imaging Methods in the Diagnosis of Pancreatic Cancer
  • 1-Oct-12 – Radioimaging in the Diagnosis of Pancreatic Cancer
  • 28-Aug-12 – EUS for Pancreatic Cancer Diagnosis
  • 24-Jul-12 – 80KV CAT Scanning Advantage for the Diagnosis of Pancreatic Cancer
  • 1-Jul-12 – EUS Needle Biopsy Procedure
  • 1-Apr-12 – Endoscopic Ultrasonography Fine-Needle Aspiration of Pancreatic Tumors
  • 1-Jan-09 – Serial CAT Scans Following the Effect of Induction Therapy of Pancreatic Cancer
  • 1-Jan-08 – Pre-surgical Diagnosis of Pancreatic Cancer

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco

MAKE AN IMPACT TODAY

All DONATIONS are tax-deductible

Our Philosophy About Pancreatic Cancer

Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

MONTHLY MEMORIAL GIFTS:  YOUR TRIBUTE TO A LOVED ONE

Regular giving can be an opportunity to pay tribute in honour of a loved one. Your monthly gift will go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer.

Simply select “Monthly” after choosing the amount you would like to give on the donation form.

Most of our fundraisers, supporters, and volunteers, have been in one way or another, personally effected by this disease. We want to acknowledge what hardships you may have gone through (or are currently facing) and sincerely thank you for visiting our site!

Join us in our effort to fight pancreatic cancer. Donations go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer. All Donations are tax-deductible. 

Join our expanding Pancreatic Cancer Community on Facebook! Connect with others, share stories, and get support! Click Here to Join!

Making IMPACT for Pancreatic Cancer Together!

MONTHLY MEMORIAL GIFTS:
Support Pancreatic Cancer Research!

Regular giving can be an opportunity to pay tribute in honour of a loved one. Your monthly gift will go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer.

Simply select “Monthly” after choosing the amount you would like to give.

Cancer Patients Alliance is a 501(c)(3) non-profit. Initiatives include, ToFightCancer.com and Pancreatica.org. All Donations are tax-deductible.

Pancreatic cancer is expected to become the 2nd leading cause of cancer-related death by the year 2020. There are many reasons why the outcome for pancreatic cancer patients is much bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options.

There remains a dire need for more research and an increase in focused funding for pancreatic cancer. Your Donation will go directly to promoting awareness, increasing education, and furthering pancreatic cancer research aimed at early diagnosis.

This year an estimated 57,600 Americans will be diagnosed with pancreatic cancer. Approximately 47,050 Americans are expected to die from the disease. There are many reasons why the outcome for pancreatic cancer patients is bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options. Which is why we are so focused on supporting research for early diagnosis.

Together with You our Mission is to promote awareness, increase education, and further pancreatic cancer research aimed at early diagnosis.

 

CREATE YOUR OWN FUNDRAISER FOR PANCREATIC CANCER !

Create your own fun, choose something you already love to support pancreatic cancer! Simply set up your participation page, include the details of your fundraiser on your page, and get the word out!

Shop to Support Pancreatic Cancer !

Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to help fight pancreatic cancer!
AmazonSmile is the same Amazon you know. Same products, same prices, same service. Simply use our Link to start shopping!

Support Pancreatic Cancer Today !

Best of the Pancreatic Cancer Blog